April 27, 2020 / 1:51 AM / 2 months ago

BRIEF-Janssen Submits NDA In Japan For Daratumumab Subcutaneous Formulation Utilizing Halozyme's Enhanze Tech For Patients With Multiple Myeloma

April 26 (Reuters) - Halozyme Therapeutics Inc:

* JANSSEN SUBMITS NDA IN JAPAN FOR DARATUMUMAB SUBCUTANEOUS FORMULATION UTILIZING HALOZYME’S ENHANZE TECH FOR PATIENTS WITH MULTIPLE MYELOMA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below